Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960957 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
A Phase 3 study of Glabellar Frown Lines, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
- 11
- Study locations
NCT03960957: Completed Phase 3 study of Glabellar Frown Lines, sponsored by Galderma R&D.
NCT03960957 is a Phase 3 study of Glabellar Frown Lines that has completed, run by Galderma R&D. The registered enrollment target is 301 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03960957, a Phase 3 study of Glabellar Frown Lines, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
- 11
- Study locations
Study Summary
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Primary Outcome
Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AbobotulinumtoxinA
Study Locations (11)
California
- Galderma Study Site - Redondo Beach
- Galderma Study Site - San Diego
Texas
- Galderma Study Site - Austin
- Galderma Study Site - Spring
Connecticut
- Galderma Study Site - Westport
District of Columbia
- Galderma Study Site - Washington D.C.
Florida
- Galderma Study Site - Coral Gables
Georgia
- Galderma Study Site - Atlanta
Missouri
- Galderma Study Site - St Louis
Nebraska
- Galderma Study Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 3 |
What the finished NCT03960957 record still lists
NCT03960957 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Glabellar Frown Lines appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03960957 lists 11 locations in 9 states (California, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03960957 about?
NCT03960957 is a clinical study titled "Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines". An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
What is the current status of trial NCT03960957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2019-06-17. Estimated completion is 2020-04-16.
What conditions does trial NCT03960957 study?
This clinical trial studies the following conditions: Glabellar Frown Lines.
What interventions are being tested in trial NCT03960957?
The interventions under investigation include: Placebo (OTHER), AbobotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03960957?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03960957 being conducted?
This trial has 11 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glabellar Frown Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03960957's enrollment target sits among peer trials
301 1121st of 2000 higher than 879 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI